Adrenopause driven by zona fasciculata-derived angiocrine suppression of zona reticularis progenitor differentiation
Hypothesis
Age‑related expansion of the zona fasciculata (ZF) secretes angiocrine factors that inhibit progenitor differentiation and migration into the zona reticularis (ZR), causing selective ZR involution and the adrenal DHEA decline termed adrenopause.
Mechanistic Rationale
- ZF expansion correlates with preserved or increased cortisol output (1; 2). Chronic ZF hyperactivity raises local cortisol and corticosterone levels within the adrenal medulla‑cortex interface.
- Glucocorticoids act on adrenal progenitor cells to suppress CYP17A1 transcription, a key enzyme for DHEA synthesis, via glucocorticoid receptor (GR)–mediated recruitment of corepressors (3).
- Expanded ZF also upregulates VEGF‑A and Angiopoietin‑2 secretion, altering the perivascular niche. Elevated VEGF‑A paradoxically promotes endothelial maturation without angiogenesis, leading to pericyte detachment and reduced oxygen delivery to the ZR compartment (4).
- Hypoxia stabilizes HIF‑1α in ZR progenitors, which further represses CYP17A1 expression and pushes cells toward apoptosis or senescence rather than differentiation.
- Sex differences arise because estrogen enhances VEGF receptor signaling in females, mitigating vascular rarefaction, whereas androgen‑driven GR activation in males amplifies the suppressive signal, explaining greater ZR loss in men (2).
Predictions and Experimental Approach
- Prediction 1: Aged mice with ZF‑specific GR knockout will show attenuated ZF hypertrophy, preserved ZR width, and higher circulating DHEAS compared with littermate controls.
- Prediction 2: Local delivery of a VEGF‑A trapping agent (e.g., aflibercept) to the adrenal capsule of aged mice will increase pericyte coverage, improve ZR oxygenation (measured by pimonidazole staining), and rescue CYP17A1‑positive cells.
- Prediction 3: Co‑culture of human adrenal progenitor cells with conditioned medium from senescent ZF‑like stromal cells will reduce CYP17A1 expression; adding a GR antagonist (mifepristone) or a HIF‑1α stabilizer inhibitor (echinomycin) will restore expression.
Experimental design: Use inducible, zonally restricted Cre lines (Cyp11b2‑Cre for ZG, Cyp11b1‑Cre for ZF, Hsd3b2‑Cre for ZR) in mice to delete Gr or Vegfa. Assess zona widths by histology, cell density by nuclei staining, serum DHEAS/CORT ratios by LC‑MS/MS, and vascular markers (CD31, NG2, HIF‑1α). In parallel, treat aged human adrenal explants with pharmacologic agents and measure CYP17A1 mRNA and DHEA secretion.
Potential Implications
If validated, this hypothesis reframes adrenopause not as passive atrophy but as an active stromal‑epithelial interaction where ZF‑derived angiocrine and glucocorticoid signals niche‑constrain ZR regeneration. Therapeutically, targeting ZF GR signaling or normalizing adrenal VEGF‑A/pericyte dynamics could restore DHEA production without systemic glucocorticoid suppression, offering a strategy to mitigate age‑related metabolic, cognitive, and immune decline linked to low DHEAS.